Evaluation of Lipid Profile in Patients with Ischemic Heart Disease


  • Zainab Mohamed Neama Department of Biology, College of Science, Kerbala University, Iraq
  • Afaf K. Shwaikh Department of Biology, College of Science, Kerbala University, Iraq




Triglycerides, HDL-c, ischemic heart disease, coronary artery disease, atherogenesis, dyslipidemia, risk prediction, personalized medicine


Ischemic heart diseases (IHDs), like coronary artery disease, remain a significant global health burden. While established risk factors such as lowdensity lipoprotein cholesterol (LDL) and hypertension are wellrecognized, the role of triglyceride (T.G.) and high-density lipoprotein cholesterol (HDL-c) remains complex and multifaceted. This work was designed to examine the role of the T.G./HDL-c ratio in the IHD group and their effect on the effect of age, gender, and biomass index (BMI). Method: A total of 90 samples, including 60 samples (30 male, 30 female) for the IHD patients group with an age range of 40-85 years, and 30 samples (15 male, 15 female) for the control group with matching age ranges, were randomly selected. Lipid profile parameters (HDL, LDL, VLDL, T.G., Cholesterol) were estimated according to Kit Shenzhen Mindray Bio— Medical Electronics—Germany's manual procedure. Then, the ratio TG/HDL-C was calculated. Results: IHD patients illustrated a significant increase in the mean levels of all lipid profile panels, including [total cholesterol (T.C.), triglyceride (T.G.), LDL, and the ratio of T.G./HDL-c], except HDL, which was lower in patients group compared to the healthy control. The level of T.G./HDLc was increased in IHD patients with increasing BMI associated with the healthy participants; it was also elevated in male IHD patients than in IHD female patients. Conclusion: The ratio of T.G./HDL-c represents a valuable indicator for valuing IHD risk and personalized therapeutic approaches. Future research should delve deeper into the underlying mechanisms and refine strategies for effectively managing T.G./HDL-c for improved IHD prevention and management.